We are live on ! Find out more
SABSW icon

SAB Biotherapeutics Warrant
SABSW

24 hedge funds and large institutions have $4.04M invested in SAB Biotherapeutics Warrant in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

2% more capital invested

Capital invested by funds: $3.97M → $4.04M (+$72K)

0% more funds holding

Funds holding: 24 → 24 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
24
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
4
Closed
4
Calls
$58K
Puts
–
Net Calls
+$58K
Net Calls Change
+$58K

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$214K
2
OCAM
Owl Creek Asset Management
New York
+$188K
3
MF
Magnetar Financial
Illinois
+$108K
4
SCM
Shaolin Capital Management
Florida
+$56.6K
5
KC
Kepos Capital
New York
+$34.6K

Top Sellers

Rank Fund Capital Flow
1
FTCM
Fir Tree Capital Management
New York
-$171K
2
PC
Periscope Capital
Ontario, Canada
-$157K
3
ICM
Ionic Capital Management
New York
-$131K
4
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$115K
5
GCL
Glazer Capital LLC
New York
-$109K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
26
Ionic Capital Management
New York
– -$131K -142,908 Closed
PMAM
27
Picton Mahoney Asset Management
Ontario, Canada
– -$115K -125,000 Closed
WAM
28
Wolverine Asset Management
Illinois
– -$10K -11,855 Closed
1
2

SABSW Hedge Fund Activity: Q3 2021 in Review

24 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q3 2021, worth a combined $4.04M — up 1.8% from $3.97M a quarter earlier.

Fund positioning in SABSW was balanced in Q3 2021: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 4 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $214K. The largest seller was Fir Tree Capital Management, exiting entirely with an estimated $171K sold.

  • 24 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $4.04M of SAB Biotherapeutics Warrant stock for Q3 2021, up 1.8% quarter-over-quarter.
  • 4 funds opened new SAB Biotherapeutics Warrant positions in Q3 2021 and 4 closed out, a net change of 0 holders.
  • The largest SAB Biotherapeutics Warrant buyer in Q3 2021 was Balyasny Asset Management, an estimated $214K added.
  • The largest SAB Biotherapeutics Warrant seller in Q3 2021 was Fir Tree Capital Management, an estimated $171K sold.

Based on aggregated 13F filings for Q3 2021.